These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 29616047)

  • 1. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
    Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.
    Rathinaswamy MK; Burke JE
    Adv Biol Regul; 2020 Jan; 75():100657. PubMed ID: 31611073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer.
    Vallejo-Díaz J; Chagoyen M; Olazabal-Morán M; González-García A; Carrera AC
    Trends Cancer; 2019 Apr; 5(4):233-244. PubMed ID: 30961830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.
    Siempelkamp BD; Rathinaswamy MK; Jenkins ML; Burke JE
    J Biol Chem; 2017 Jul; 292(29):12256-12266. PubMed ID: 28515318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.
    Geering B; Cutillas PR; Nock G; Gharbi SI; Vanhaesebroeck B
    Proc Natl Acad Sci U S A; 2007 May; 104(19):7809-14. PubMed ID: 17470792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
    Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
    Hon WC; Berndt A; Williams RL
    Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
    Lucas CL; Zhang Y; Venida A; Wang Y; Hughes J; McElwee J; Butrick M; Matthews H; Price S; Biancalana M; Wang X; Richards M; Pozos T; Barlan I; Ozen A; Rao VK; Su HC; Lenardo MJ
    J Exp Med; 2014 Dec; 211(13):2537-47. PubMed ID: 25488983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
    Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
    Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
    Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K pathway defects leading to immunodeficiency and immune dysregulation.
    Nunes-Santos CJ; Uzel G; Rosenzweig SD
    J Allergy Clin Immunol; 2019 May; 143(5):1676-1687. PubMed ID: 31060715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
    Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
    Front Immunol; 2019; 10():77. PubMed ID: 30891027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
    Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
    Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors.
    Tsolakos N; Durrant TN; Chessa T; Suire SM; Oxley D; Kulkarni S; Downward J; Perisic O; Williams RL; Stephens L; Hawkins PT
    Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12176-12181. PubMed ID: 30442661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
    Hofmann BT; Jücker M
    Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class IA PI3K regulatory subunits: p110-independent roles and structures.
    Fox M; Mott HR; Owen D
    Biochem Soc Trans; 2020 Aug; 48(4):1397-1417. PubMed ID: 32677674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins.
    Wang P; Kumar P; Wang C; Defea KA
    Biochem J; 2007 Dec; 408(2):221-30. PubMed ID: 17680774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.